Fig. 5 | Scientific Reports

Fig. 5

From: Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

Fig. 5

Effects of QR-KLU combined with anti-PD-1 antibody on the growth of subcutaneous Hepa1–6 tumor in mice (n = 6). (A) Schematic diagram of the timing of intervention in Hepa1–6 tumor-bearing mice (drawn using Figdraw, export ID: YAPYSe1e88). (B) Tumor growth curve. (C) Bar chart of tumor volume at the last measurement. PD-1 programmed cell death receptor-1, QR-KLU peptide (QR)–drug (KLU) conjugate.

Back to article page